Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Porton Pharma Solutions Ltd. (300363.SZ)
CNY18.86
+0.53 (+2.89%)
CN SHZ Healthcare Biotechnology
Address
Fangzheng Avenue
Chongqing, CN
Chongqing, CN
CEO
Nianfeng Ju
Website
porton.cn
IPO
2014-01-29
ISIN CNE100001S57
Description
Porton Pharma Solutions Ltd. caters to pharmaceutical companies by manufacturing and supplying a diverse portfolio of products, which encompasses small molecule active pharmaceutical ingredients (APIs), drug intermediates, various dosage forms, and biologics. The company was formerly known as Porton Fine Chemicals Ltd. until it adopted its current name in January 2018. Established in 2005, Porton Pharma Solutions Ltd. operates from its headquarters in Chongqing, China.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
CNY18.86
+0.53 (+2.89%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
18M
Beta
0.42
Float Shares
322.22M
Free Float %
59.3%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.54% | -3.15% | -30.50% | -37.33% | -38.07% | -36.57% | -6.47% | -52.70% | -77.63% | -23.19% | +52.90% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
18.86
DCF (Levered)
0.38
-98.0%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
2.74
Grey zone
Piotroski F-Score
7 / 9
Strong
MOAT Score
2 / 10
No MOAT
Composite Rating
B
Overall Score
3 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
3 / 5
Medium
ROA Score
4 / 5
High
D/E Score
2 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+13.0% ★ Q1'26: +10.6% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+134.0% ★ Q1'26: +614.0% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%+7.9% Q1'26: -1.7% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%+3.5% ★ Q1'26: +3.3% (vs Q1'25)
-
ROIC Biotechnology: -16.1%+1.2% ★ Q1'26: +1.2% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%-0.1% ★ Q1'26: +26.6% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×3.12× Q1'26: 15.89× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 2 Rev. Ana. 2 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
1.02B
est: 1.36B (-25.0%)
|
1.33B
est: 1.33B (0.0%)
|
1.18B
est: 1.42B (-16.6%)
|
1.18B
est: 1.16B (+2.5%)
|
1.55B
est: 1.55B (0.0%)
|
2.07B
est: 2.06B (+0.4%)
|
3.11B
est: 3.05B (+1.8%)
|
7.03B
est: 7.14B (-1.5%)
|
3.67B
est: 2.68B (+36.8%)
|
3.01B
est: 2.98B (+1.2%)
|
3.40B
est: 3.49B (-2.4%)
|
3.88B
3.82B – 3.94B
+11.3% YoY
|
4.38B
4.25B – 4.50B
+12.8% YoY
|
4.90B
4.90B – 4.91B
+12.0% YoY
|
| EBITDA |
205.13M
est: 275.44M (-25.5%)
|
311.77M
est: 268.28M (+16.2%)
|
285.67M
est: 286.88M (-0.4%)
|
236.59M
est: 233.71M (+1.2%)
|
295.37M
est: 313.63M (-5.8%)
|
497.81M
est: 417.37M (+19.3%)
|
719.86M
est: 616.38M (+16.8%)
|
2.45B
est: 1.44B (+69.9%)
|
580.68M
est: 506.31M (+14.7%)
|
95.90M
est: 561.91M (-82.9%)
|
591.21M
est: 658.55M (-10.2%)
|
732.91M
721.45M – 744.36M
+11.3% YoY
|
826.40M
802.36M – 850.44M
+12.8% YoY
|
925.84M
924.61M – 927.07M
+12.0% YoY
|
| EBIT |
149.15M
est: 184.32M (-19.1%)
|
232.37M
est: 179.53M (+29.4%)
|
169.48M
est: 191.98M (-11.7%)
|
111.94M
est: 156.40M (-28.4%)
|
178.49M
est: 209.88M (-15.0%)
|
366.69M
est: 279.30M (+31.3%)
|
555.88M
est: 412.48M (+34.8%)
|
2.22B
est: 966.11M (+129.5%)
|
291.88M
est: 286.45M (+1.9%)
|
-224.00M
est: 317.91M (-170.5%)
|
118.42M
est: 372.59M (-68.2%)
|
414.65M
408.17M – 421.14M
+11.3% YoY
|
467.55M
453.95M – 481.15M
+12.8% YoY
|
523.81M
523.11M – 524.50M
+12.0% YoY
|
| Net Income |
110.39M
est: 246.13M (-55.1%)
|
171.19M
est: 257.89M (-33.6%)
|
107.45M
est: 222.60M (-51.7%)
|
124.49M
est: 130.30M (-4.5%)
|
185.55M
est: 173.74M (+6.8%)
|
324.42M
est: 290.29M (+11.8%)
|
523.92M
est: 516.58M (+1.4%)
|
2.01B
est: 1.84B (+8.7%)
|
266.86M
est: -313.55M (+185.1%)
|
-287.75M
est: -240.37M (-19.7%)
|
96.34M
est: 70.48M (+36.7%)
|
227.72M
223.09M – 232.34M
+223.1% YoY
|
374.11M
366.50M – 381.71M
+64.3% YoY
|
460.85M
451.49M – 470.22M
+23.2% YoY
|
| SGA |
162.44M
est: 206.97M (-21.5%)
|
237.67M
est: 201.59M (+17.9%)
|
161.69M
est: 215.57M (-25.0%)
|
174.41M
est: 175.62M (-0.7%)
|
233.25M
est: 235.67M (-1.0%)
|
303.65M
est: 313.63M (-3.2%)
|
385.07M
est: 463.17M (-16.9%)
|
807.66M
est: 1.08B (-25.5%)
|
693.17M
est: 411.03M (+68.6%)
|
557.81M
est: 456.16M (+22.3%)
|
522.61M
est: 534.62M (-2.2%)
|
594.98M
585.68M – 604.28M
+11.3% YoY
|
670.88M
651.36M – 690.39M
+12.8% YoY
|
751.60M
750.61M – 752.60M
+12.0% YoY
|
| EPS |
0.27
est: 0.45 (-40.4%)
|
0.41
est: 0.48 (-13.7%)
|
0.25
est: 0.41 (-39.0%)
|
0.26
est: 0.24 (+8.3%)
|
0.35
est: 0.32 (+9.4%)
|
0.61
est: 0.53 (+14.1%)
|
0.98
est: 0.95 (+3.0%)
|
3.70
est: 3.40 (+8.9%)
|
0.49
est: -0.57 (+185.8%)
|
-0.53
est: -0.44 (-19.5%)
|
0.18
est: 0.13 (+38.5%)
|
0.42
0.41 – 0.43
+223.1% YoY
|
0.69
0.68 – 0.70
+64.3% YoY
|
0.85
0.83 – 0.87
+23.2% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-28 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-27 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-26 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-25 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-22 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-21 | B- | 3/5 | 2/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-20 | B- | 3/5 | 2/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-19 | B- | 3/5 | 2/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-18 | B- | 3/5 | 2/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-15 | B- | 3/5 | 2/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-14 | B- | 3/5 | 2/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-13 | B- | 3/5 | 2/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-12 | B- | 3/5 | 2/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-11 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-08 | C+ | 2/5 | 1/5 | 2/5 | 3/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-07 | C+ | 2/5 | 1/5 | 2/5 | 3/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-06 | C+ | 2/5 | 1/5 | 2/5 | 3/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-30 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-29 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-28 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-27 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-24 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-23 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-22 | C+ | 2/5 | 2/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-21 | B- | 2/5 | 3/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-20 | B- | 2/5 | 3/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-17 | B- | 2/5 | 3/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-16 | B- | 2/5 | 3/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
803.83M
OE per share TTM
1.57
Owner's Yield
10.06%
Maintenance CapEx ratio
200.33%
Maint CapEx / Avg PPE
87.4%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 24 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | State Street SPDR S&P Emerging Markets Small Cap ETF EWX | 0.01% | 60.1K | 0.65% |
| 2 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 274.4K | 0.29% |
| 3 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 251.6K | 0.39% |
| 4 | Schwab Emerging Markets Equity ETF SCHE | 0.00% | 158.7K | 0.06% |
| 5 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 9.9K | 0.48% |
| 6 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 22.3K | 0.26% |
| 7 | Vanguard FTSE Emerging Markets UCITS ETF (USD) Accumulating VFEA.L | 0.00% | 40.2K | 0.17% |
| 8 | Vanguard FTSE Emerging Markets UCITS ETF (USD) Distributing VDEM.L | 0.00% | 40.2K | 0.17% |
| 9 | Vanguard FTSE Emerging Markets ETF VWO | 0.00% | 1.10M | 0.06% |
| 10 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 58.8K | 0.28% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
24.1K
Shares Outstanding
543.44M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Hui Chen | Deputy GM & Chief Financial Officer | — | male |
| Nianfeng Ju | Chairman & GM | — | male |
| Po Zhu | Deputy General Manager | — | male |
| Qi Chen | Deputy General Manager | — | male |
| Wei Pi | Deputy GM & Secretary of the Board of Directors | — | female |
| Ya Qian Ruan | Accounting Supervisor | — | — |
| Yinchun Bai | Senior Deputy GM, COO & Employee Representative Director | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 300363.SZ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
